Robert Kidder - Merck Independent Director

MRK Stock  USD 131.95  0.20  0.15%   

Director

Mr. C. Robert Kidder is Independent Director of Merck Co., Inc. Mr. Kidder was Chairman of the Board of Directors, Chrysler Group LLC from 2009 to 2011 since 2005.
Age 71
Tenure 19 years
Address 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
Phone908 740 4000
Webhttps://www.merck.com
Kidder also served as Chairman and Chief Executive Officer of 3Stone Advisors LLC from 2006 to 2011 and was a Principal of Stonehenge Partners, Inc. from 2004 to 2006. Director, Morgan Stanley since 1994, Microvi Biotech Inc. since 2008 and Wildcat Discovery Technologies, Inc. since 2012 ; Board of Trustees, Nationwide Children’s Hospital since 1998 and Wexner Center for the Arts Foundation since 1999.

Merck Management Efficiency

The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Capital Employed is expected to slide to 0.04. The value of Return On Assets is estimated to slide to 0. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.
The company has 36.27 B in debt with debt to equity (D/E) ratio of 0.68, which is OK given its current industry classification. Merck Company has a current ratio of 1.43, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Americo Romano23Andme Holding Co
58
Paul ClarkAgilent Technologies
72
Arturo Testa23Andme Holding Co
37
Stephen ConnellyEquillium
42
David BerrySeres Therapeutics
37
Mark PruzanskiEquillium
50
Meryl ZausnerSeres Therapeutics
61
Johannes Tiden23Andme Holding Co
34
Bala ManianEquillium
72
Roy Blom23Andme Holding Co
65
Anthony TjanEquillium
N/A
Robert HerboldAgilent Technologies
74
Charles McDermottEquillium
45
Staffan Gavel23Andme Holding Co
67
Bo Eriksson23Andme Holding Co
65
Mala AnandAgilent Technologies
53
Scott MorensteinMadrigal Pharmaceuticals
38
James DalyMadrigal Pharmaceuticals
N/A
Peter HuttSeres Therapeutics
80
Kurt GravesSeres Therapeutics
50
Salvatore Falco23Andme Holding Co
46
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. Merck Company (MRK) is traded on New York Stock Exchange in USA. It is located in 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 and employs 70,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scot Ebbinghaus, VP Development
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Caroline Litchfield, Chief Financial Officer, Executive Vice President
Mirian GraddickWeir, Executive Vice President - Human Resources
Jannie Oosthuizen, Lead - Human Health U.S.
Jennifer Mauer, VP Communications
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Gregory Lubiniecki, VP Development
Michael Klobuchar, Executive Vice President Chief Strategy Officer
Patricia Russo, Independent Director
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
William Harrison, Lead Independent Director
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Deepak Khanna, Lead - Human Health International
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Gideon Blumenthal, Vice Affairs
Adam Schechter, President of Global Human Health and Executive VP
Risa LavizzoMourey, Independent Director
Thomas Glocer, Lead Independent Director
Craig Thompson, Independent Director
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Arpa Garay, Lead - Human Health Global Marketing
Dalton III, Principal Finance
Christine Seidman, Independent Director
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Chirfi Guindo, Senior Health
Joerg Koglin, Vice Development
Stephen Mayo, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Peter Dannenbaum, Vice Relations
Clark Golestani, CIO and Executive VP
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer
Robert JD, President Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Merck Investors Sentiment

The influence of Merck's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Merck. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Merck's public news can be used to forecast risks associated with an investment in Merck. The trend in average sentiment can be used to explain how an investor holding Merck can time the market purely based on public headlines and social activities around Merck Company. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Merck's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Merck's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Merck's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Merck.

Merck Implied Volatility

    
  51.56  
Merck's implied volatility exposes the market's sentiment of Merck Company stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Merck's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Merck stock will not fluctuate a lot when Merck's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.453
Dividend Share
2.92
Earnings Share
0.14
Revenue Per Share
23.695
Quarterly Revenue Growth
0.058
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.